HIV 101: Initiation of Antiretroviral Therapy and Primary Care for People With HIV (On-Demand)

Assessment of Needs

This webinar is designed for HIV or infectious disease residents, fellows, and advanced practitioners who are new to the field of HIV research and management. In the webinar, experts in the field will describe the core principles of HIV management, including pathogenesis of HIV infection, mechanism of action of antiretroviral drugs, initiating antiretroviral therapy, and primary care for people with HIV. This webinar will also be useful to experienced clinicians who seek a review of these core principles.

Learning Objectives

At the end of this webinar, participants will be able to:

• Describe basic mechanisms of antiretroviral therapy
• Describe antiretroviral regimens based on patient parameters
• Conduct an initial assessment for a person with HIV
• Provide appropriate vaccinations for people with HIV, focusing on pneumococcus, hepatitis B, SARS-CoV-2, and monkeypox
• Assess cardiovascular risk in people with HIV
• Screen for and manage polypharmacy and frailty

Preactivity

View the on-demand recording of our webinar on the Fundamentals of HIV Infections and Application of Antiretroviral Therapy, presented on September 29, 2021, by Michael S. Saag, MD of the University of Alabama at Birmingham. Complete the preactivity assessment here.

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are in training, new to, or are interested in a review of HIV patient care, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Though attendance for the 2022 Ryan White HIV/AIDS CLINICAL CONFERENCE is limited to HIV physicians, nurse practitioners, physician assistants, and primary clinical decision makers in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs, registration for this webinar is open to all.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenters

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 07/19/22)

Dr Thompson’s institution has received research grants from Gilead Sciences, Inc, Merck Sharp Dohme, and ViiV Healthcare. She has served on advisory and data safety monitoring boards for Excision Biotherapeutics. (Updated 07/19/22)

Planner/Reviewer

Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 07/19/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 07/19/22)